×

Themes

Biologic Therapy

A novel case of combination biologic therapy for treatment of refractory palmoplantar pustulosis
A novel case of combination biologic therapy for treatment of refractory palmoplantar pustulosis
Alexander Tedman, Ken Maguire, Christina Sander
Dupilumab Treatment for up to 3 Years Demonstrates Sustained Efficacy and Favorable Safety in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From LIBERTY AD Adult OLE
Dupilumab Treatment for up to 3 Years Demonstrates Sustained Efficacy and Favorable Safety in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Results From LIBERTY AD Adult OLE
Andrew Blauvelt, Iftikhar Hussain, Xiaoping Zhu, Bethany Beazley, Naimish Patel
Successful treatment of refractory type I pityriasis rubra pilaris with ustekinumab
Successful treatment of refractory type I pityriasis rubra pilaris with ustekinumab
Nicholas Allen, Annika Smith
Long-Term Efficacy and Safety of Dupilumab in Adolescents With Atopic Dermatitis: Results From an Open-Label Extension Trial (LIBERTY AD PED-OLE)
Long-Term Efficacy and Safety of Dupilumab in Adolescents With Atopic Dermatitis: Results From an Open-Label Extension Trial (LIBERTY AD PED-OLE)
Andrew Blauvelt, Emma Guttman-Yassky, Iftikhar Hussain, RIchard Worrell, Zhen Chen
Adalimumab induced interstitial lung disease in a patient with pityriasis rubra pilaris
Adalimumab induced interstitial lung disease in a patient with pityriasis rubra pilaris
Hannah Gribbin, Leith  Banney , Jazlyn  Read 
Dupilumab in Children Aged >6 to <12 years Significantly Improves Severe Atopic Dermatitis: Results From Phase 3 Trial (LIBERTY AD PEDS)
Dupilumab in Children Aged >6 to <12 years Significantly Improves Severe Atopic Dermatitis: Results From Phase 3 Trial (LIBERTY AD PEDS)
Melinda Gooderham, Mark Boguniewicz, Lawrence Sher, Jamie Weisman, Ashish Bansal
Two novel cases of palmoplantar pompholyx in the context of secukinumab therapy for chronic plaque psoriasis.
Two novel cases of palmoplantar pompholyx in the context of secukinumab therapy for chronic plaque psoriasis.
Melissa Peera, Annika Smith
Ultra-low dose rituximab in pemphigus: a single centre experience.
Ultra-low dose rituximab in pemphigus: a single centre experience.
Kate Simpson, Zhi Mei Low, Yonatan Kok, Tami Yap, Johannes Kern
A case of lichenoid photodermatitis developing secondary to nivolumab therapy
A case of lichenoid photodermatitis developing secondary to nivolumab therapy
Akshay Flora, Margot Whitfeld
A case of Metastatic Crohn's Disease responding to Infliximab: A rare dermatologic entity of Crohn's Disease
A case of Metastatic Crohn's Disease responding to Infliximab: A rare dermatologic entity of Crohn's Disease
Ali Didan, Alan Donnelly
Successful treatment of hypocomplementaemic urticarial vasculitis syndrome (HUVS) with omalizumab
Successful treatment of hypocomplementaemic urticarial vasculitis syndrome (HUVS) with omalizumab
Niluka Dilrukshi Paththinige, Dedee F Murrell
Anti-TNF Treatments for Women with Chronic Inflammatory Diseases: Attitudes and Perceptions of Dermatologists in Australia
Anti-TNF Treatments for Women with Chronic Inflammatory Diseases: Attitudes and Perceptions of Dermatologists in Australia
Monisha Gupta, Lynda Spelman, Annika Smith, Alfred Lanzafame
Drug Induced Bullous Pemphigoid, in a patient with a New Diagnosis of Myasthenia Gravis
Drug Induced Bullous Pemphigoid, in a patient with a New Diagnosis of Myasthenia Gravis
Ramez Barsoum, Erin McMeniman, Peter Soyer
Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Safety and Efficacy of Tildrakizumab, a High-Affinity Anti-Interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
Philip J Mease, Saima Chohan, Ferran J García Fructuoso, Alice B Gottlieb, Richard C Chou
Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23/interleukin-17 pathway in the pathogenesis of lichen planus
Clinical healing of erosive oral lichen planus with tildrakizumab implicates the interleukin-23/interleukin-17 pathway in the pathogenesis of lichen planus
Fathima Ferial Ismail, Rodney Sinclair
Effective treatment of eosinophilic dermatosis of haematological malignancy with Montelukast
Effective treatment of eosinophilic dermatosis of haematological malignancy with Montelukast
Loren Besley, Rohan Mortimore, Laura Wheller
Successful treatment of refractory folliculitis decalvans with secukinumab
Successful treatment of refractory folliculitis decalvans with secukinumab
Fathima Ferial Ismail, Rodney Sinclair
Secukinumab treatment of Parry Romberg Syndrome
Secukinumab treatment of Parry Romberg Syndrome
Emily Sideris, Sally de Zwaan
Refractory Lupus Erythematosus Tumidus responsive to tildrakizumab
Refractory Lupus Erythematosus Tumidus responsive to tildrakizumab
Fathima Ferial Ismail, Joel Pinczewski, Rodney Sinclair
A case of pityriasis rubra pilaris treated with secukinumab: The widening scope of biologics in dermatology
A case of pityriasis rubra pilaris treated with secukinumab: The widening scope of biologics in dermatology
Subashini Gnanendran, Diana Rubel
Nanotechnology in dermatology
Nanotechnology in dermatology
Anthony D Honigman, Matthew J Lin
Case Report: Repigmentation of vitiligo with oral baricitinib
Case Report: Repigmentation of vitiligo with oral baricitinib
Blake Mumford, Alvin H Chong
Neurological adverse effects of biologic treatments used for psoriasis or psoriatic arthritis: a systematic review and meta-analysis
Neurological adverse effects of biologic treatments used for psoriasis or psoriatic arthritis: a systematic review and meta-analysis
Angelica Tjokrowidjaja, Edmund Chung, Gillian Marshman
THE EFFECT OF ORAL AND TOPICAL JANUS KINASE INHIBITORS ON ALOPECIA AREATA - A SYSTEMATIC REVIEW
THE EFFECT OF ORAL AND TOPICAL JANUS KINASE INHIBITORS ON ALOPECIA AREATA - A SYSTEMATIC REVIEW
Charan Jeet Arora, Dee Dee Murrell
Adult cervicofacial nocardiosis in the setting of IL-12/23 blockade
Adult cervicofacial nocardiosis in the setting of IL-12/23 blockade
Geoffrey Lee, Roselle Robosa, Gloria Fong, Frederick Lee,, Angie Pinto
The efficacy and safety of Tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomized clinical trials.
The efficacy and safety of Tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomized clinical trials.
Charan Jeet Arora, Stephen Shumack
A case of granuloma annulare associated with secukinumab use in psoriasis
A case of granuloma annulare associated with secukinumab use in psoriasis
William Berry, Benjamin Daniel, Peter Foley
Refractory discoid lupus erythematosus responds to rituximab: a case report
Refractory discoid lupus erythematosus responds to rituximab: a case report
Blake Mumford, Zahra Assarian, Alvin H Chong
Repigmentation in vitiligo with Janus kinase (JAK) inhibitors may improve with concomitant light exposure
Repigmentation in vitiligo with Janus kinase (JAK) inhibitors may improve with concomitant light exposure
Kevin Phan, Monisha Gupta
Short-term efficacy of tildrakizumab in the treatment of patients with moderate to severe Hidradenitis Suppurativa: A small observational study
Short-term efficacy of tildrakizumab in the treatment of patients with moderate to severe Hidradenitis Suppurativa: A small observational study
Yonatan Kok, Jenny Nicolopoulos, Zhi Mei Low, Anne Howard, George Varigos
Managing PASH syndrome with tildrakizumab: A potential novel therapeutic target
Managing PASH syndrome with tildrakizumab: A potential novel therapeutic target
Yonatan Kok, Jenny Nicolopoulos, George Varigos, Anne  Howard, Con Dolianitis
The efficacy and immunogenicity of anti-TNFɑ inhibitors in refractory granuloma annulare
The efficacy and immunogenicity of anti-TNFɑ inhibitors in refractory granuloma annulare
Anita Smith, Grace Thompson, Jamie Von Nida
Toxoplasmosis in a patient on ixekizumab for psoriasis
Toxoplasmosis in a patient on ixekizumab for psoriasis
Yolanka Lobo, Teagan Holland, Lynda  Spelman 
The real world drug survival of biologic therapies in Australasian Psoriasis Registry patients
The real world drug survival of biologic therapies in Australasian Psoriasis Registry patients
Simon Cumming, Peter Foley, Chris Baker
12-month cost comparison of dupilumab treatment versus alternatives for severe atopic dermatitis
12-month cost comparison of dupilumab treatment versus alternatives for severe atopic dermatitis
Harrison Edwards, Erin K McMeniman
Skin manifestations of zinc deficiency in patients receiving EGFRIs
Skin manifestations of zinc deficiency in patients receiving EGFRIs
Chaw-Ning Lee, Frank Po-Chao Chiu, Chao-Kai Hsu
Successful treatment of recalcitrant lichen planus pemphigoides with Tildrakizumab
Successful treatment of recalcitrant lichen planus pemphigoides with Tildrakizumab
Karolina Kerkemeyer, Rodney Sinclair
Bullous pemphigoid in a young patient during treatment with adalimumab
Bullous pemphigoid in a young patient during treatment with adalimumab
Milan van Ammers, Francis XY Lai, Adrian Mar
Hidradenitis Suppurativa recurrence in a caesarean scar: A case report and review of the literature.
Hidradenitis Suppurativa recurrence in a caesarean scar: A case report and review of the literature.
Katherine M Darch, Lynda Spelman
Secukinumab induced bowel disease: A case report and review of the literature.
Secukinumab induced bowel disease: A case report and review of the literature.
Katherine M Darch, Lynda Spelman
Not so easy on the eyes. A case report and review of the literature regarding eye disease in patients treated with dupilumab (Dupixent), a novel biologic agent targeting the IL-4Ra for moderate-to-severe atopic dermatitis.
Not so easy on the eyes. A case report and review of the literature regarding eye disease in patients treated with dupilumab (Dupixent), a novel biologic agent targeting the IL-4Ra for moderate-to-severe atopic dermatitis.
Katherine M Darch, Braden D Meiklejohn, Lynda J Spelman
Hitting the nail on the head: An update on nail disease in psoriasis and review of evidence for the use of biologic agents for its treatment.
Hitting the nail on the head: An update on nail disease in psoriasis and review of evidence for the use of biologic agents for its treatment.
Katherine M Darch, Lynda Spelman
Ustekinumab and Tildrakizumab in Pyoderma Gangrenosum
Ustekinumab and Tildrakizumab in Pyoderma Gangrenosum
Tabrez Sheriff, Dedee F Murrell


No presentations found for today.